Mirnela Byku

Invasive Hemodynamics Reveal Hidden Risk in Ambulatory Patients with Heart Failure

Nicholas Ashur, Mirnela Byku

Despite decades of therapeutic advances, heart failure (HF) remains a leading cause of morbidity and mortality worldwide, underscoring the need for refined tools to identify patients at highest risk for adverse outcomes. Although HF remains a syndrome defined by clinical signs and …

us (code pays fourni par la source)

Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation

Jason N. Katz, Jean M. Connors, Francis D. Pagani, Ulrich P. Jorde et autres

BACKGROUND: The ARIES-HM3 (Antiplatelet Removal and Hemocompatibility Events With the HeartMate 3 Pump) trial demonstrated safety and decreased bleeding in eliminating aspirin from the antithrombotic regimen of patients implanted with a HM3 left ventricular assist device (LVAD). Whether pharmacologic therapies impact hemocompatibility-related …

us, cz (code pays fourni par la source)

Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial

Jean M. Connors, Finn Gustafsson, Nir Uriel, Francis D. Pagani et autres

BACKGROUND AND AIMS: Left ventricular assist devices (LVADs), including the HeartMate 3 (HM3), have improved outcomes in patients with advanced heart failure. Use of vitamin K antagonists (VKA) is mandated to reduce the risk of thrombotic events, but there is heterogeneity in …

us, dk, cz, at, ca (code pays fourni par la source)

Outcomes and Tolerability of Early Mammalian Target of Rapamycin Inhibitor Initiation for Renal Sparing in Heart Transplant Recipients

Rachel Rikard, C. William Castor, Margeaux Meilhac, Patricia P. Chang et autres

PURPOSE: Renal dysfunction in heart transplant recipients (HTRs) is a significant post-transplant complication. This study aims to assess the effects of early mammalian target of rapamycin inhibitor (mTORi) initiation on renal and graft outcomes in HTRs. METHODS: A single-center retrospective analysis of …

us (code pays fourni par la source)

Heterogeneity in HeartMate 3 implanting center infection management reveals opportunities for quality improvement and best practice initiatives during left ventricular assist device support

Jennifer Cowger, Sarah Schettle, Francis D. Pagani, Farooq H. Sheikh et autres

BACKGROUND: There is marked variability in device-related (DR) infection frequencies across HeartMate 3 (HM3) centers. The goal is to correlate center driveline (DL) management and infection mitigation practices with DR-infection development, laying foundation for development of best practice recommendations for one facet …

us (code pays fourni par la source)

COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine

Alanna A. Morris, Mirnela Byku, Nathan W. Cummins, Sony Tuteja et autres

us (code pays fourni par la source)

Relationship of PAD and Use of TMCS on Outcomes Post-LVAD: A Case Series of 197 Patients

Panagiotis Tasoudis, M WILLIAMS, Amrita Sukhavasi, Steven A. Buckeridge et autres

As left ventricular assist device (LVAD) use expands to include more critically ill patients, identifying and mitigating preoperative risk factors, such as peripheral arterial disease (PAD) and use of temporary mechanical circulatory support (tMCS) essential. This retrospective cohort study included patients who …

us (code pays fourni par la source)

Hemodynamics of left ventricular assist device implantation

Jason N. Katz, Mirnela Byku

The modern history of left ventricular (LV) assist devices (LVAD) dates back to the late 1970s and early 1980s with the development of the Jarvik artificial heart. There are multiple factors that should be considered when assessing a patient's eligibility for LVAD. …

Abstract 4137107: The Impact of Race in the Evaluation Process for Advanced Heart Failure Therapies

Dalton Sherwood, Khoula Saleem, C A Wills, Mirnela Byku et autres

Introduction: Racial and socioeconomic disparities in heart failure therapy and heart transplantation have been well described. Potential racial disparities during the evaluation process for advanced heart failure (AHF) therapies is not well understood. We examined whether there were differences by race in …

us (code pays fourni par la source)

Use of mechanical circulatory support and survival for heart and heart-kidney transplant recipients in the new allocation system

Aurélie Merlo, Mirnela Byku, Zhentao Yu, Hannah F. Bensimhon et autres

us (code pays fourni par la source)

An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device

Ian B. Hollis, Douglas L. Jennings, Selim R. Krim, Van‐Khue Ton et autres

us, ca, de, ee, au, in, es, nl (code pays fourni par la source)

RECOGNIZING AN OMINOUS GENETIC CARDIOMYOPATHY TOO LATE: THE HIGH-RISK FLNC GENE MUTATION

Marykate Carrillo, Spencer Ng, Mirnela Byku

us (code pays fourni par la source)